Xconomy: Dendreon has only itself to blame for Provenge fiasco

Xconomy's Luke Timmerman takes Dendreon to task for its acknowledged blunder marketing Provenge. Chiding the biotech for overreaching on price, failing to get its marketing ducks in a row ahead of an approval and fumbling its outreach to physicians, Timmerman adds that Dendreon's ($DNDN) failure is limited to a single company, with more experienced players like Vertex (Incivek) and Bristol-Myers Squibb (Yervoy) finding success with their new drugs. Of course, their success also begs the question whether Dendreon had fully explained all the reasons for Provenge's sudden disappointment. And today, on another bad day on Wall Street, Dendreon's battered shared slid another 11 percent. Column

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.